Examining potential therapies targeting myocardial fibrosis through the inhibition of transforming growth factor-beta 1

Cardiology

Volumn 108, Issue 4, 2007, Pages 368-380

  Khan, Razi ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Collagen; Endothelin; Growth hormone; Hepatocyte growth factor; Myocardial fibrosis; NADPH oxidase; Natriuretic peptides; Nitric oxide; Relaxin; Transforming growth factor beta 1

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN RECEPTOR ANTAGONIST; GROWTH HORMONE; NATRIURETIC FACTOR; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RELAXIN; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ENZYME INHIBITION; HEART FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMYOPATHIES; ENDOTHELINS; ENZYME INHIBITORS; FIBROSIS; GROWTH HORMONE; HEPATOCYTE GROWTH FACTOR; HUMANS; MYOCARDIUM; NADPH OXIDASE; NATRIURETIC PEPTIDES; NITRIC OXIDE; RELAXIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34548842251     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099111     Document Type: Review

References (147)

1. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;3:569-582.
2. Jugdutt BI: Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 2003;108:1395-1403.
3. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;8:1161-1172.
4. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005;115:209-218.
5. Lucattelli M, Bartalesi B, Cavarra E, Fineschi S, Lunghi B, Martorana PA, Lungarella G: Is neutrophil elastase the missing link between emphysema and fibrosis? Evidence from two mouse models. Respir Res 2005;6:83.
6. Imai E, Isaka Y, Akagi Y, Kaneda Y, Hori M: Gene transfer and kidney disease. J Nephrol 1998;11:16-19.
7. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF: Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996;148:1639-1648.
8. Deten A, Holzl A, Leicht M, Barth W, Zimmer HG: Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol 2001;33:1191-1207.
9. Hao J, Ju H, Zhao S, Junaid A, Scammell-La Fleur T, Dixon IM: Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 1999;31:667-678.
10. Li G, Borger MA, Williams WG, Weisel RD, Mickle DA, Wigle ED, Li RK: Regional overexpression of insulin-like growth factor-I and transforming growth factor-beta1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg 2002;123:89-95.
11. Di Nardo P, Fiaccavento R, Natali A, Minieri M, Sampaolesi M, Fusco A, Janmot C, Cuda G, Carbone A, Rogliani P, Peruzzi G: Embryonic gene expression in nonoverloaded ventricles of hereditary hypertrophic cardiomyopathic hamsters. Lab Invest 1997;77:489-502.
12. Sanderson JE, Lai KB, Shum IO, Wei S, Chow LT: Transforming growth factor beta(1) expression in dilated cardiomyopathy. Heart 2001;86:701-708.
13. Holweg CT, Baan CC, Niesters HG, Vantrimpont PJ, Mulder PG, Maat AP, Weimar W, Balk AH: TGF-beta1 gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant 2001;20:979-984.
14. Dixon IM, Hao J, Reid NL, Roth JC: Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res 2000;46:286-297.
15. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH: Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993;88:2849-2861.
16. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ: Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 1995;27:2347-2357.
17. Kupfahl C, Pink D, Friedrich K, Zurbrugg HR, Neuss M, Warnecke C, Fielitz J, Graf K, Fleck E, Regitz-Zagrosek V: Angiotensin II directly increases transforming growth factor beta 1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res 2000;46:463-475.
18. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H: Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 1995;25:1252-1259.
19. Rosenkranz S: TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004;63:423-432.
20. Juan W, Nakazawa M, Watanabe K, Ma M, Wahed MI, Hasegawa G, Naito M, Yamamoto T, Fuse K, Kato K, Kodama M, Aizawa Y: Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. Mol Cell Biochem 2003;251:77-82.
21. Ma M, Watanabe K, Wahed MI, Inoue M, Sekiguchi T, Kouda T, Ohta Y, Nakazawa M, Yoshida Y, Yamamoto T, Hanawa H, Kodama M, Fuse K, Aizawa Y: Inhibition of progression of heart failure and expression of TGF-beta 1 mRNA in rats with heart failure by the ACE inhibitor quinapril. J Cardiovasc Pharmacol 2001;38:S51-S54.
22. Hallberg P, Lind L, Billberger K, Michaelsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Liljedahl U, Syvanen AC, Melhus H: Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment - results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol 2004;27:169-173.
23. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T: Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
24. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D: NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005;97:900-907.
25. Tzanidis A, Lim S, Hannan RD, See F, Ugoni AM, Krum H: Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1). J Mol Cell Cardiol 2001;33:969-981.
26. Smith RS Jr, Agata J, Xia CF, Chao L, Chao J: Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci 2005;7621:2457-2471.
27. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J, Tregear GW, Du XJ: Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004;145:4125-4133.
28. Imanishi R, Ashizawa N, Ohtsuru A, Seto S, Akiyama-Uchida Y, Kawano H, Kuroda H, Nakashima M, Saenko VA, Yamashita S, Yano K: GH suppresses TGF-beta-mediated fibrosis and retains cardiac diastolic function. Mol Cell Endocrinol 2004;218:137-146.
29. Nakamura T, Matsumoto K, Mizuno S, Sawa Y, Matsuda H, Nakamura T: Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol 2005;288:H2131-H2139.
30. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-348.
31. Laviades C, Varo N, Diez J: Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000;36:517-522.
32. Rankin JS, Arentzen CE, McHale PA, Ling D, Anderson RW: Viscoelastic properties of the diastolic left ventricle in the conscious dog. Circ Res 1977;41:37-45.
33. Burlew BS, Weber KT: Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002;27:92-98.
34. Ohsato K, Shimizu M, Sugihara N, Konishi K, Takeda R: Histopathological factors related to diastolic function in myocardial hypertrophy. Jpn Circ J 1992;56:325-333.
35. Brilla CG, Funck RC, Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-1393.
36. McLenachan JM, Dargie HJ: Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990;3:735-740.
37. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kuhl U, Schultheiss HP: Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999;99:2750-2756.
38. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
39. Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation 2000;102:2700-2706.
40. Gullestad L, Aukrust P: Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005;95:17C-23C.
41. Nagasawa K, Zimmerman R, Westernacher D, Schaper J: Angiotensin II induced collagen mRNA expression in cardiac fibroblasts depends on autocrine production of transforming growth factor-beta 1 (abstract). J Am Coll Cardiol 1994;23:43A.
42. Koyanagi M, Egashira K, Kubo-Inoue M, Usui M, Kitamoto S, Tomita H, Shimokawa H, Takeshita A: Role of transforming growth factor-beta1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension 2000;35:86-90.
43. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A: Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by longterm blockade of nitric oxide synthesis in rats. Hypertension 1998;32:273-279.
44. Kilby JM: Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors. Expert Opin Investig Drugs 1999;8:1157-1170.
45. Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S, Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H: Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 2005;111:2430-2437.
46. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, Takeshita A: Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004;64:526-535.
47. Mujumdar VS, Tyagi SC: Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens 1999;17:261-270.
48. Simkhovich BZ, Marjoram P, Poizat C, Kedes L, Kloner RA: Age-related changes of cardiac gene expression following myocardial ischemia/reperfusion. Arch Biochem Biophys 2003;420:268-278.
49. Weis SM, Zimmerman SD, Shah M, Covell JW, Omens JH, Ross J Jr, Dalton N, Jones Y, Reed CC, Iozzo RV, McCulloch AD: A role for decorin in the remodeling of myocardial infarction. Matrix Biol 2005;24:313-324.
50. Costacurta A, Priante G, D'Angelo A, Chieco-Bianchi L, Cantaro S: Decorin transfection in human mesangial cells downregulates genes playing a role in the progression of fibrosis. J Clin Lab Anal 2002;16:178-186.
51. Fischer JW, Kinsella MG, Clowes MM, Lara S, Clowes AW, Wight TN: Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats. Circ Res 2000;86:676-683.
52. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
53. Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD: Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 1997;54:1205-1216.
54. Beck S, Le Good JA, Guzman M, Ben Haim N, Roy K, Beermann F, Constam DB: Extra-embryonic proteases regulate Nodal signalling during gastrulation. Nat Cell Biol 2002;4:981-985.
55. Bressan GM, Daga-Gordini D, Colombatti A, Castellani I, Marigo V, Volpin D: Emilin, a component of elastic fibers preferentially located at the elastin-microfibrils interface. J Cell Biol 1993;121:201-212.
56. Zacchigna L, Vecchione C, Notte A, Cordenonsi M, Dupont S, Maretto S, Cifelli G, Ferrari A, Maffei A, Fabbro C, Braghetta P, Marino G, Selvetella G, Aretini A, Colonnese C, Bettarini U, Russo G, Soligo S, Adorno M, Bonaldo P, Volpin D, Piccolo S, Lembo G, Bressan GM: Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 2006;124:929-942.
57. Colombatti A, Bressan GM, Castellani I, Volpin D: Glycoprotein 115, a glycoprotein isolated from chick blood vessels, is widely distributed in connective tissue. J Cell Biol 1985;100:18-26.
58. Amma LL, Goodyear R, Faris JS, Jones I, Ng L, Richardson G, Forrest D: An emilin family extracellular matrix protein identified in the cochlear basilar membrane. Mol Cell Neurosci 2003;23:460-472.
59. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griendling KK: Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002;22:21-27.
60. Akar FG, Aon MA, Tomaselli GF, O'Rourke B: The mitochondrial origin of postischemic arrhythmias. J Clin Invest 2005;115:3527-3535.
61. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM: Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 2003;93:802-805.
62. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ: Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993;14:1493-1498.
63. Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M, Laufs U: Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003;108:1567-1574.
64. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM: Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003;41:2164-2171.
65. Rocic P, Lucchesi PA: NAD(P)H oxidases and TGF-beta-induced cardiac fibroblast differentiation: Nox-4 gets Smad. Circ Res 2005;97:850-852.
66. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM: Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002;105:293-296.
67. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS: Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 1998;40:352-363.
68. Luscher TF: Endothelin, endothelin receptors, and endothelin antagonists. Curr Opin Nephrol Hypertens 1994;3:92-98.
69. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT: Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993;27:2130-2134.
70. Tonnessen T, Christensen G, Oie E, Holt E, Kjekshus H, Smiseth OA, Sejersted OM, Attramadal H: Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats. Cardiovasc Res 1997;33:601-610.
71. Tonnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, Christensen G: Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res 1995;76:767-772.
72. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ: Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995;147:325-338.
73. Miyauchi T, Fujimori A, Maeda S, Iemitsu M, Sakai S, Shikama H, Tanabe T, Matsuda M, Goto K, Yamaguchi I: Chronic administration of an endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure. J Cardiovasc Pharmacol 2004;44:S64-S67.
74. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, Thuillez C: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976-1982.
75. Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M: ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 2005;45:1145-1152.
76. Fraccarollo D, Galuppo P, Bauersachs J, Ertl G: Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res 2002;54:559-567.
77. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL: Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension 2002;39:679-684.
78. van Wamel AJ, Ruwhof C, van der Valk-Kokshoorn LJ, Schrier PI, van der Laarse A: Stretch-induced paracrine hypertrophic stimuli increase TGF-beta1 expression in cardiomyocytes. Mol Cell Biochem 2002;236:147-153.
79. Lund AK, Peterson SL, Timmins GS, Walker MK: Endothelin-1-mediated increase in reactive oxygen species and nadph oxidase activity in hearts of aryl hydrocarbon receptor (AhR) null mice. Toxicol Sci 2005;88:265-273.
80. Rodriguez-Pascual F, Redondo-Horcajo M, Lamas S: Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res 2003;92:1288-1295.
81. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H, Yazaki Y: Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989;159:1435-1440.
82. Yan RT, White M, Yan AT, Yusuf S, Rouleau JL, Maggioni AP, Hall C, Latini R, Afzal R, Floras J, Masson S, McKelvie RS; Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Investigators: Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 2005;96:698-704.
83. Nishikimi T, Maeda N, Matsuoka H: The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006;69:318-328.
84. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M: Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000;97:4239-4244.
85. Franco V, Chen YF, Oparil S, Feng JA, Wang D, Hage F, Perry G: Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension 2004;44:746-750.
86. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K: Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 2002;106:1722-1728.
87. Nakanishi M, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Kawakami R, Nakagawa Y, Tanimoto K, Yasuno S, Usami S, Li Y, Adachi Y, Fukamizu A, Garbers DL, Nakao K: Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 2005;46:441-447.
88. Takahashi N, Saito Y, Kuwahara K, Harada M, Kishimoto I, Ogawa Y, Kawakami R, Nakagawa Y, Nakanishi M, Nakao K: Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. Hypertens Res 2003;26:847-853.
89. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA: B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004;94:453-461.
90. Hayashi D, Kudoh S, Shiojima I, Zou Y, Harada K, Shimoyama M, Imai Y, Monzen K, Yamazaki T, Yazaki Y, Nagai R, Komuro I: Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochem Biophys Res Commun 2004;322:310-309.
91. Schulz R, Triggle CR: Role of NO in vascular smooth muscle and cardiac muscle function. Trends Pharmacol Sci 1994;15:255-259.
92. Ritchie RH, Schiebinger RJ, LaPointe MC, Marsh JD: Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol 1998;275:H1370-H1374.
93. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-2701.
94. Dusting GJ, Selemidis S, Jiang F: Mechanisms for suppressing NADPH oxidase in the vascular wall. Mem Inst Oswaldo Cruz 2005;100(suppl 1):97-103.
95. Zhang JJ, Bledsoe G, Kato K, Chao L, Chao J: Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 2004;66:722-732.
96. Itagaki T, Shimizu I, Cheng X, Yuan Y, Oshio A, Tamaki K, Fukuno H, Honda H, Okamura Y, Ito S: Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress-induced activation of cultured rat hepatic stellate cells. Gut 2005;54:1782-1789.
97. 2 stress triggers a release of transforming growth factor-beta 1, which induces biomarkers of cellular senescence of human diploid fibroblasts. J Biol Chem 2001;276:2531-2537.
98. Jardine H, MacNee W, Donaldson K, Rahman I: Molecular mechanism of transforming growth factor (TGF)-1-induced glutathione depletion in alveolar epithelial cells. J Biol Chem 2002;277:21158-21166.
99. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJ: Activation of orphan receptors by the hormone relaxin. Science 2002;295:671-674.
100. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW: Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc Res 2003;57:395-404.
101. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, Stangl K: The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001;15:2187-2195.
102. Zhang J, Qi YF, Geng B, Pan CS, Zhao J, Chen L, Yang J, Chang JK, Tang CS: Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 2005;26:1632-1639.
103. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, Bathgate RA, Du XJ, Samuel CS: Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005;46:412-418.
104. Failli P, Nistri S, Quattrone S, Mazzetti L, Bigazzi M, Sacchi TB, Bani D: Relaxin upregulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. FASEB J 2002;16:252-254.
105. Heeg MH, Koziolek MJ, Vasko R, Schaefer L, Sharma K, Muller GA, Strutz F: The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 2005;68:96-109.
106. Novak J, Ramirez RJ, Gandley RE, Sherwood OD, Conrad KP: Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats. Am J Physiol Regul Integr Comp Physiol 2002;283:R349-R355.
107. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS: Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996;93:800-809.
108. Bruel A, Oxlund H: The effect of growth hormone on rat myocardial collagen. Growth Horm IGF Res 1999;9:123-130.
109. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334:809-814.
110. Cittadini A, Grossman JD, Napoli R, Katz SE, Stromer H, Smith RJ, Clark R, Morgan JP, Douglas PS: Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997;29:1109-1116.
111. Grimm D, Cameron D, Griese DP, Riegger GA, Kromer EP: Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovasc Res 1998;40:297-306.
112. Akiyama-Uchida Y, Ashizawa N, Ohtsuru A, Seto S, Tsukazaki T, Kikuchi H, Yamashita S, Yano K: Norepinephrine enhances fibrosis mediated by TGF-β in cardiac fibroblasts. Hypertension 2002;40:148-154.
113. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G: The heart: an end-organ of GH action. Eur J Endocrinol 2004;151(suppl 1):S93-S101.
114. Fausto N, Laird AD, Webber EM: Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995;9:1527-1536.
115. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, Fujimoto J: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-230.
116. Wang Y, Ahmad N, Wani MA, Ashraf M: Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis. J Mol Cell Cardiol 2004;37:1041-1052.
117. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Chatterjee S, Berry MF, Burdick J, Gardner TJ, Sweeney HL: Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003;108(suppl 1):II230-II236.
118. Li Y, Takemura G, Kosai K, Yuge K, Nagano S, Esaki M, Goto K, Takahashi T, Hayakawa K, Koda M, Kawase Y, Maruyama R, Okada H, Minatoguchi S, Mizuguchi H, Fujiwara T, Fujiwara H: Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003;107:2499-2506.
119. Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, Fujii T, Uematsu M, Ohgushi H, Yamagishi M, Tokudome T, Mori H, Miyatake K, Kitamura S: Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005;112:1128-1135.
120. Purdie KJ, Whitley GS, Johnstone AP, Cartwright JE: Hepatocyte growth factor-induced endothelial cell motility is mediated by the upregulation of inducible nitric oxide synthase expression. Cardiovasc Res 2002;54:659-668.
121. Metais C, Li J, Li J, Simons M, Sellke FW: Effects of coronary artery disease on expression and microvascular response to VEGF. Am J Physiol 1998;275:H1411-H1418.
122. Mizuno S, Nakamura T: Suppressions of chronic glomerular injuries and TGF-1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol 2004;286:F134-F143.
123. Yang J, Dai C, Liu Y: A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005;16:68-78.
124. Yang J, Dai C, Liu Y: Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 2003;163:621-632.
125. Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169-178.
126. Hao J, Wang B, Jones SC, Jassal DS, Dixon IM: Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 2000;279:H3020-H3030.
127. Dixon IM, Hao J, Reid NL, Roth JC: Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res 2000;46:286-297.
128. Weber KT, Pick R, Silver MA, Moe GW, Janicki JS, Zucker IH, Armstrong PW: Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 1990;82:1387-1401.
129. Emery JL, Omens JH: Mechanical regulation of myocardial growth during volume-overload hypertrophy in the rat. Am J Physiol 1997;273:H1198-H1204.
130. Borer JS, Truter S, Herrold EM, Falcone DJ, Pena M, Carter JN, Dumlao TF, Lee JA, Supino PG: Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular responses to volume overload. Circulation 2002;105:1837-1842.
131. Krieglstein K, Henheik P, Farkas L, Jaszai J, Galter D, Krohn K, Unsicker K: GDNF requires TGF-β for establishing its neurotrophic activity. J Neurosci 1998;18:9822-9834.
132. Roberts AB, Sporn MB: The transforming growth factors-β; in Sporn MB, Roberts AB (eds): Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors. New York, Springer, 1990, pp 419-472.
133. Kehrl JH, Wakefield LM, Roberts AB: Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163:1037-1050.
134. Luethviksson BR, Gunnlaugsdottir B: Transforming growth factor-beta as a regulator of site-specific T-cell inflammatory response. Scand J Immunol 2003;58:129-138.
135. Jiang X, Zeng HS, Guo Y, Zhou ZB, Tang BS, Li FK: The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (Engl) 2004;117:1825-1829.
136. Cipollone F, Fazia M, Mincione G, Iezzi A, Pini B, Cuccurullo C, Ucchino S, Spigonardo F, Di Nisio M, Cuccurullo F, Mezzetti A, Porreca E: Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke 2004;35:2253-2257.
137. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-774.
138. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T: Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-699.
139. Scherf W, Burdach S, Hansen G: Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model. Eur J Immunol 2005;35:198-206.
140. Chen H, Sun J, Buckley S, Chen C, Warburton D, Wang XF, Shi W: Abnormal mouse lung alveolarization caused by Smad3 deficiency is a developmental antecedent of centrilobular emphysema. Am J Physiol Lung Cell Mol Physiol 2005;288:L683-L691.
141. Geiser AG, Zeng QQ, Sato M, Helvering LM, Hirano T, Turner CH: Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene. Bone 1998;23:87-93.
142. Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga C, Warters R, Akhurst RJ, Barcellos-Hoff MH: Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res 2002;62:5627-5631.
143. Massague J, Blain SW, Lo RS: TGF-beta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
144. Kim SJ, Im YH, Markowitz SD, Bang YJ: Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 2000;11:159-168.
145. Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, Letterio JJ, Wakefield LM: Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998;4:802-807.
146. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA: TGFbeta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
147. Massagué J: TGF-β signal transduction. Annu Rev Biochem 1998;67:753-791.